Electro-hyperthermia device Supplier includes: OncoTherm EHY-3010, OncoTherm, Troisdorf, Germany

This capacitive radiofrequency system (13.56 MHz) is designed to preferentially deliver energy to malignant tissue by exploiting impedance differences between tumors and surrounding healthy tissue. The approach aims to increase metabolic stress within cancer cells while limiting heat exposure to the skin and nearby normal structures.

Local and whole-body hyperthermia is intended to elevate tumor temperature to cytotoxic levels, disrupt protein folding, impair DNA repair, and improve tumor perfusion, which in turn may enhance oxygen and drug delivery.

• Whole-body hyperthermia involves the controlled and gradual elevation of core body temperature using external heating technologies.
• Treatments are designed to be gentle and well tolerated, with monitoring of temperature, comfort, and vital signs throughout the session.
• Mild therapeutic heating may support circulation, tissue perfusion, and physiological stress responses.
• Hyperthermia is being investigated for its potential to enhance the effects of certain conventional therapies, including chemotherapy, radiotherapy, and immunotherapy.
• It may also influence immune activity and cellular repair or stress-response mechanisms.
• Whole-body hyperthermia is typically used as a complementary approach within broader treatment strategies rather than as a standalone therapy.

Heckel HT-3000 system (Hydrosun Medizintechnik GmbH, Germany).

Modern electromagnetic heating techniques allow hyperthermia to be precisely controlled and directed at tumor areas, helping to promote the destruction of cancer cells while minimizing unwanted side effects. Research has also demonstrated that hyperthermia can enhance the effectiveness of various chemotherapy drugs. When used alongside radiation therapy, studies indicate that hyperthermia can produce complementary and additive therapeutic benefits. In addition, evidence suggests that hyperthermia may strengthen the immune system’s ability to respond to and fight cancer.

Hyperthermia, locally increasing body temperature to 42 °C or higher, exploits heat sensitivity of cancer cells and causes direct cytotoxicity. Hyperthermia has been shown to increase the efficacy of radiotherapy and some chemotherapeutic agents by sensitizing cancer cells to these therapies; and some chemotherapeutic agents have shown synergism with hyperthermia, including both carboplatin and paclitaxel